|
Owners and Tenants
Progress Corporate Park is home to over 30 companies. These
range in size from 500-sqare foot one-person laboratories
to a high tech medical manufacturing company with over 300
employees occupying up to 110,000-square feet.
Some of these companies are outgrowths of technology developments
made by the University of Florida. Others have relocated here
in order to utilize the talented and skilled labor force to
be found around such a major research university.
COMPANIES IN PROGRESS CENTER
13709 PROGRESS BOULEVARD
ALACHUA, FL 32615
THE FOUNDATION for APPLIED MOLECULAR
EVOLUTION (FfAME) is a non-profit center for polydisciplinary
research in science and technology, emphasizing distinctive
combinations of the molecular, life and planetary sciences.
At our laboratory at the Progress Corporate Park we are researching
technologies to make DNA sequencing cheaper, synthesize genes
faster, and support a new generation of genomics research
and personalized medicine. This research is funded through
small business technology transfer (STTR) grants from NIH
and collaborations with several biotechnology companies. Contact:
Daniel Hutter, 13709 Progress Blvd, Suite N112, Alachua, FL
32615, (386) 418-8085, fax (352) 271-7076.
Postal address: PO Box 13174, Gainesville, FL 32614, Email:
dhutter@ffame.org, Web:
www.ffame.org
INNOVATION PARTNERS, LTD. As owners and
developers of Progress Corporate Park, we strive to accommodate
and encourage business and technological advancement in Alachua,
Florida. For more information regarding land availability
or established business or lab accommodations in high profile
first rate surroundings please contact Sandy Burgess, 13709
Progress Boulevard, Box 10, Alachua, FL 32615, (386) 462-4040
or e-mail sandy@progresscorporatepark.com
or visit our website at www.progresscorporatepark.com.
IXION BIOTECHNOLOGY, INC. is a discovery
research biotechnology company, founded in 1993. We have worldwide
exclusive licenses to two distinct patented technologies addressing
two major untreated diseases: diabetes and kidney stones.
Contact: Dr. Stephen Bartelmez, President and Chief Executive
Officer. 13709 Progress Boulevard, Box 13, Ste. 108, Alachua,
FL 32615, (386) 462-2326, fax (386) 462-3080 or info@ixion-biotech.com.
NOVAMIN TECHNOLOGY, INC. markets its proprietary
oral healthcare active ingredient to toothpaste and dental
products marketers around the world. NovaMin addresses the
oral healthcare needs of adults by reducing sensitivity, gingivitis
and mineral loss. Contact: Randy Scott CEO, NovaMin Technology
Inc., 13709 Progress Blvd.#23 Alachua FL 32615 Phone: 386-418-1551.
www.novamin.com
NOVABONE PRODUCTS, LLC specializes in synthetic
grafting materials for the repair of bone defects in oral,
craniofacial and orthopedic use. Our synthetic bone
graft materials are sold under the brand names PerioGlas®,
NovaBone-C/M®, and NovaBone®. These devices
are composed of a unique bioactive composition that stimulates
and accelerates bone repair. Contact: Sandra Allen,
13709 Progress Boulevard, Box 33, Alachua, FL 32615
(386) 462-7660, fax (386) 418-1636. Email: info@novabone.com
or www.novabone.com.
OXTHERA, INC. is a clinical stage biotechnology
company based in Sweden and Florida. The company develops
products based on its cell and enzyme based proprietary technologies,
for metabolic disorders based on excess oxalate from endogenous
and exogenous sources. OxThera will market and sell its orphan
drug products to treat and prevent hyperoxaluria and kidney
stones in indications such as Primary and Enteric Hyperoxaluria.
Contact: Jon Heimer, President. 13709 Progress Blvd, Box 17,
Alachua, FL 32615, (386) 418-1428, fax: (386) 418-1583. Website:
www.oxthera.com.
PARTICLE SOLUTIONS, LLC is engage in the
research and development of silica and mixed oxide nanoparticles
and monodispersed powders. These powders are used as a raw
material and building block for a wide variety of products
and applications and are sold across many different markets
ranging from Research and Development at Universities, to
Biomedical, Electronic and Photonic applications. We also
develop value-added products for our customers using these
powder systems. Contact: Layne Howell, 13709 Progress Boulevard,
Box 36, Alachua, FL 32615, (407) 221-7119, email: LHowell810@bellsouth.net
PEGASUS BIOLOGICS, INC. manufactures, sterilizes
and markets specialized, advanced Bioimplants for use in orthopedic
muscuskeletal applications, sports medicine, neurosurgery,
and spine surgery. Pegasus' R&D facility is located in
the Progress Corporate Center in Alachua and its operations
are located in Irvine, CA. 13709 Progress Blvd, Box 34, Suite
127, Alachua, FL 32615, (386) 462-3217, fax: (386) 462-0914.
Web: www.pegasusbio.com.
TUTOGEN MEDICAL, INC. manufactures sterile
biological implant products made from human (allograft) and
animal (xenograft) tissue. Tutogen utilizes its proprietary
Tutoplast Process® of tissue preservation and viral inactivation
to produce and deliver sterile bio-implants used in spinal/trauma,
urology, dental, ophthalmology, and general surgery procedures.
The Company's Tutoplast® products are sold and distributed
worldwide by Zimmer Spine and Zimmer Dental (subsidiaries
of Zimmer Holdings, Inc.), the Mentor Corporation, IOP, Inc.,
Davol (division of C.R. Bard) and through independent distributors
and subsidiaries in the U.S. and other international markets.
For more information, visit the Company's website at www.tutogen.com
or contact Claude Pering, 13709 Progress Boulevard, Box 19,
Alachua, FL 32615; telephone (386) 462-0402, facsimile (386)
462-1421.
LARGE ANIMAL FACILITY
12550 RESEARCH DRIVE
ALACHUA, FL 32615
LARGE ANIMAL FACILITY, laboratory and housing
equipped to handle large animals for vaccine testing and or
disease research. Contact number: (386) 462-5172.
REGENERATION TECHNOLOGIES, INC.
11621 RESEARCH CIRCLE
ALACHUA, FL 32615
REGENERATION TECHNOLOGIES, INC. (RTI) a
spin-off of the University of Florida Tissue Bank, Inc. (UFTB),
was founded in February 1998 to provide focused support to
the research and development of tissue technology and to process
allograft and xenograph tissue for transplantation. The company
processes tissue into shaped implants for use in orthopedic
and other surgeries, providing innovative, natural options
for surgeons and their patients. Contact: 11621 Research Circle,
Alachua, FL 32615, (386) 418-8888 or www.rtix.com.
CP AMERICA INTERNATIONAL
11801 RESEARCH DRIVE
ALACHUA, FL 32615
CP AMERICA INTERNATIONAL. One of the world’s
largest network of independent CPA and consulting firms—sharing
knowledge, resources and information to better serve member
CPA firms and their clients. Contact: Doug Thompson, President
and CEO, 11801 Research Drive, Alachua, FL 32615, (386) 418-4001
www.cpamerica.org or e-mail dthompson@cpamerica.org.
CPA MUTUAL. A nationwide professional liability
insurance company owned and directed solely by its member
insured CPAs. Contact: Bill Thompson, President and CEO. 11801
Research Drive, Alachua, FL 32615, (386) 418-4121
www.cpamutual.com or e-mail bthompson@cpamutual.com.
FMC DIALYSIS CENTER OF ALACHUA
11550 RESEARCH CIRCLE
ALACHUA, FL 32615
FMC DIALYSIS CENTER provides dialysis services
to area patients. Contact: 11550 Research Circle, Alachua,
FL 32615, (386) 418-2235.
INTERMED ULTRASOUND SERVICES, INC.
INTERMED BIOMEDICAL SERVICES, INC.
INTERMED X-RAY, INC.
13351 Progress Boulevard
ALACHUA, FL 32615
INTERMED provides effective solutions to
the Medical community for Radiology, Imaging, Biomedical and
Ultrasound equipment. A one source service for parts, preventative
maintenance, equipment installations, ASP service, technical
consulting and PACS Implementation. Contact: Intermed, Inc.
13351 Progress Boulevard, Alachua, FL 32615, (386) 462-5220
or 1 (800) 768-8622 or visit our website at
www.intermed1.com.
TUCKER-DAVIS TECHNOLOGIES
11930 RESEARCH CIRCLE
ALACHUA, FL 32615
TUCKER-DAVIS TECHNOLOGIES develops, manufactures
and markets a complete line of PC-based signal processing
systems used to study human biological systems in a variety
of research areas. Contact: Tammy Smyder (386) 462-9622, fax
(386) 462-5365, or e-mail address, info@tdt.com
or visit the website www.tdt.com
HYDROSPHERE RESEARCH, INC
11842 Research Circle
Alachua, FL 32615
HYDROSPHERE RESEARCH, INC. (386) 462-7889,
craig@hydrosphere.net,
www.hydrosphere.net
ORAGENICS, INC.
13700 PROGRESS BLVD.
ALACHUA, FL 32615
ORAGENICS, INC. is developing two technologies
that address major markets. The Company's Replacement Therapy
is designed to control and eliminate dental caries by replacing
the cavity-causing Streptococcus mutans bacteria with a genetically
modified strain of the bacteria that will not cause tooth
decay. Animal studies are underway; human clinical trials
are expected to begin in 2004. The second technology is a
new generation antibiotic. Antibiotic-resistant bacteria have
become the greatest threat to effective health care today.
Oragenics is developing a robust antibiotic, mutacin 1140
that kills bacterial pathogens without any evidence to date
of resistance from the target pathogen. Both technologies
were created by Oragenics founder, Dr. Jeffrey Hillman, and
they have been licensed from the University of Florida. Contact:
(386) 418-4018, www.oragenics.com.
COMPANIES LOCATED AT THE
UF SID MARTIN BIOTECHNOLOGY
DEVELOPMENT INCUBATOR
12085 RESEARCH DRIVE
ALACHUA, FL 32615
(386) 462-0880
Contact:
Ms. Patti Breedlove
Incubator Manager
(386) 462-0880
Fax: (386) 462-0875
www.biotech.ufl.org
AXOGEN NERVE REGENERATION is a biomedical
company developing products that will allow surgeons to repair
and regenerate peripheral nerves more successfully than ever
before. Every year in the US, several million people suffer
peripheral nerve injuries, a major source of disability that
impairs the ability to move muscles or to feel normal sensations.
AxoGen, utilizing a seasoned management team with a strong
track record, is revolutionizing peripheral nerve procedures
based on scientific breakthroughs that reveal the mechanism
of axon growth and regeneration. Contact: Jamie Grooms, CEO,
352-244-5813, jmgrooms@cox.net
BANYAN BIOMARKERS, INC’ is focused
on commercializing novel biomarker in vitro diagnostic products
to address unmet clinical needs associated with organ injury.
Our initial diagnostic products will be used for the detection
and monitoring of traumatic brain injury (TBI). Until now,
no simple, point-of-care blood test existed for use by physicians
in the emergency room or in the hospital to detect the presence
and severity of brain trauma. Banyan research has identified
unique and proprietary biomarkers present in the patient's
blood following injury to the brain. Detecting these
biomarkers will provide early indications of brain trauma
essential for earlier intervention and management. Banyan's
other development program includes biomarker tests for other
injured organs such as heart, liver and lungs.
Contact: Gary Ascani, CEO, 386-462-2481. www.banyanbio.com.
BIOENERGY INTERNATIONAL, LLC, headquartered
in Norwell, Massachusetts is a privately held, biotechnology
company committed to develop and deliver advanced technologies
to produce clean, environmentally beneficial fuels and specialty
chemicals from traditional feedstocks and cellulose. BioEnergy
currently has under development a pipeline of novel biocatalysts
and two 108 million gallon per year ethanol plants which,
over time, will utilize its proprietary technologies to produce
high value specialty chemicals and renewable fuels.Contact:
Joseph Glas, SVP Research & Development, 781-681-5050,
www.bioenergyllc.com.
BIOMED IMMUNOTECH, INC. is a start
up immune technologic company in biological medicine, which
specializes in providing the services of quantitative analysis
of T cell receptor (TCR) repertoire spectratyping to researchers
and clinicians. The analysis can accurately display internal
characteristics of T cell immune response to HIV, EBV, CMV
and other viral infections, autoimmune diseases, tumors, and
bone marrow transplantation without the need for in vitro
growth of T cells. The company is also specialized in developing
diagnostic/prognostic markers and TCR based immunotherapy
for human diseases based on its platform technologies. Contact:
Zhong Kou, CEO, 386.462,9277, zkou@biotech.ufl.org.
CELUNOL CORP. is a biotechnology company
that has developed and is engaged in the commercialization
of technology that converts low or zero cost agricultural,
woody and fibrous materials into fuel ethanol using patented
bio-engineered organisms. The U.S. market for fuel ethanol,
which passed 5 billion gallons in 2006, is projected to grow
rapidly over the next decade to meet President Bush's goal
of a 20% reduction in gasoline use by 2017. Celunol's high-yield
production process is expected to offer large operating cost
advantages over conventional production methods, which use
corn or petroleum as feedstock, and will sharply reduce exposure
to feedstock price volatility. Development work at the BDI
is currently supporting Celunol's construction of a 1.4-million
gallon/yr. ethanol plant near Jennings, LA, targeted for startup
in early 2008. Successful completion of this demonstration-scale
plant is expected to pave the way for several commercial-scale
developments.Contact: Gregory Luli, 386.418.4050, gluli@celunol.com,
www.celunol.com.
ECOARRAY, LLC is developing a proprietary
genomics database that can be used to make a number of related
products including environmental testing gene arrays, contract
analysis, laboratory test kits, and human toxicology testing
products. Widespread public concern about chemicals found
in the environment that may act as endocrine disruptors has
resulted in a governmental mandate to develop assays to monitor
for these compounds. Analysis of contaminants at the gene
level is particularly useful in monitoring for endocrine disruptors
since the main effect of hormones is to alter gene expression.
Contact: John Rogers, CEO, 386.418.1400, johnro@biotech.ufl.org,
www.ecoarray.com.
INTEGRATED PLANT GENETICS, INC. is a development
stage biotechnology company in business to develop, produce
and license genetic technologies for horticultural, agricultural
and food production industries. IPG is developing environmentally
sound and sustainable genetic alternatives to make plants
resistant to diseases without using costly and toxic chemical
pest control. IPG’s unique genetic modification approaches
are designed and developed to be safe for human and animal
consumption. According to the Grocery Manufacture’s
Association, over 70% of the groceries in U.S. shelves are
already made with some genetically engineered component. IPG
is also the first and only agricultural genetic engineering
company in Florida, the second largest agriculture products
producing state in the U.S. Contact: Dean Gabriel, CEO, 386.418.3494,
ipg@biotech.ufl.org,
www.ipgenetics.com.
NANOMEDEX, INC., uses nanotechnology
to research and develop novel methods of medical diagnostics
and therapeutics. As an initial focus, NanoMedex, Inc. is
developing proprietary nanotechnology designed to improve
the current formulations of clinically relevant, off patent
lipophilic drugs such as propofol, the most frequently used
intravenous anesthetic. Contact: 386.462.5740.
NANOTHERAPEUTICS INC. is a specialty biopharmaceutical
company applying unique formulation nanotechnologies to create
novel and enhanced drug delivery solutions for new and approved
drug compounds. The Company's technologies increase bioavailability
and improve dispersion for most classes of drugs. Further
advantages over competing nanoparticle processing technologies
include consistent size distribution, gentle processing, increased
stability and scalability. The current pipeline includes an
oral formulation of a drug for pain, inhaled and topical antibiotic
formulations, as well as an FDA-cleared injectible orthopedic
product. Contact: Chuck Soponis, CEO, 386.462.9663, csoponis@nanotherapeutics.com,
www.nanotherapeutics.com
PASTEURIA BIOSCIENCE, LLC is an early-stage
agricultural biotechnology company formed to address the world’s
largest unmet pest-control problem: plant-parasitic nematodes.
Our proprietary technology allows the in-vitro growth
and sporulation of Pasteuria penetrans, a naturally-occurring
nematode pathogen, for nematode control in crops ranging from
high-value ornamentals to agronomic staples. Contact: Kelly
S. Smith, President and CEO, 386.462.0008, Ksmith@biotech.ufl.org,
www.pasteuriabio.com.
RFE PHARMA, INC., will provide physicians
with innovative somatostatin drugs to treat unmet medical
needs in patients suffering from cancer, diabetes, central
nervous system (CNS) and gastrointestinal (GI) diseases. The
company is developing the world’s first peptidomimetic
somatostatin drug products to improve the quality of life
in patients who currently rely on expensive, injectable peptide
drug medications. A class of high potency drugs has been designed
to make the established benefits of somatostatin therapy affordable
and widely available. RFE’s broader mission is
to extend the scope of somatostatin therapy. Products for
chronic application are being tailored for improved management
of metastatic cancer, diabetic retinopathy and gastrointestinal
disease states. As a new milestone in medicine, the company
is pioneering the world’s first CNS active somatostatin
diagnostics and drugs for epilepsy and mental health disorders.
Contact: Gideon Shapiro, CEO (386) 462-4323, gshapiro@somatocor.com.
GRADUATES
Applied Genetic Technologies, Corp., (AGTC), Contact: Sue
Washer, CEO, 386.462.2204.
EnCor Biotechnology, Inc., Contact: Gerry Shaw, CSO, shaw@mbi.ufl.edu
EraGen Biosciences, Inc., Contact: Irene Hrusovsky,
M.D., President & CEO, 608.662.9000.
Global Laboratories, Inc., Contact: Masoumeh Rajabi, 352.372.0436,
maser@abcr.com
Ixion Biotechnology, Inc., Contact: Robert Harris, 386.418.1428,
info@ixion-biotech.com.
Oxthera, Inc., Contact: Jon Heimer, CEO, 386.418.1428, jon.heimer@oxthera.co
Oragenics, Inc., Contact: Dr. Robert Zahradnik, CEO, 386.418.4018,
rzahradnik@oragenics.com,
www.oragenics.com.
SunPharm, Inc., (Acquired), Contact: Genzyme, 781.290.5888.
Universal Air Technologies, Inc., (Acquired) Contact:Lennox
Industries, 352.379-9630.
ASSOCIATE MEMBERS
Exactech, Inc. Contact: Dr. Steve Lin, VP Advanced Technology
& Business Development, 352.377.1140.
Life Sciences, Inc., Contact: Mr. Alex Burns, VP, 727.345.9371.
Regeneration Technologies, Inc., Contact: Ron Cobb, 386.418.8888
ext. 4186, rcobb@rtix.com
13400 PROGRESS BOULEVARD,
CONTEMPORARY MANAGEMENT CONCEPTS, INC.
(386) 462-7179, FAX: (386) 462-5109
WWW.CMCAPT.COM
Founded in 1979, CONTEMPORARY MANAGEMENT CONCEPTS,
INC.,provides full service marketing, consulting
and financial expertise in the field of apartment complex
development and management.
Contemporary Mangagement Concepts, Inc. manages over 3,500
apartment units valued at more than $110,000,000. Our goal
is to maximize clients initial investment and optimize their
return through efficient on-site management. Debbie E. MacLeod,
President and Owner, employs a management team of twelve professionals,
each excelling in their field of knowledge.
From conceptual planning and development to daily management
practices, Contemporary Management Concepts, Inc. is with
you every step of the way.
ALESYS
13500 PROGRESS BOULEVARD
ALACHUA, FL 32615
ALESYS is a learning effectiveness organization
that assists our Customers in achieving their vision by implementing
custom designed and developed training programs and processes
to meet strategic business goals and objectives. We
work closely with our Customers to develop highly effective
technical and "soft" skills training that enables
employees and management to perform their jobs with more skill
and success. Our products and services are customized
to the specific needs and performance goals of each Customer
and are often proprietary to that Customer. 13500 Progress
Blvd., Alachua, FL 32615. Contact: Marnie Feasel,
Senior Partner at 386.462.5562 ext. 22, 386.462.5546 fax,
or email: mfeasel@alesys.com.
Visit our website at www.alesys.com.
11706 INNOVATION DRIVE
UF CENTER OF EXCELLENCE FOR REGENERATIVE HEALTH BIOTECHNOLOGY
P.O. BOX 110580, GAINESVILLE, FL 32611-0580
352-846-2398, Fax: 352 392-4290
Web: http://cerhb.rgp.ufl.edu/
13702 INNOVATION DRIVE
FLORIDA BIOLOGIX
(877) 765-7676
INFO@FLORIDABIOLOGIX.COM
|
